A long-acting modified glucagon peptide analog or its salt and its use

By developing a long-acting modified glucagon peptide analog with dual agonism of glucagon/glucagon-like peptide-1 receptor, the existing obesity treatment drugs have limited effects and great side effects. Problem, significant weight loss and blood sugar control effects were achieved.

CN112898404BActive Publication Date: 2024-11-12TIANJIN INSTITUTE OF PHARMA RESEARCH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201911218802.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2019-12-03
Publication Date
2024-11-12
Estimated Expiration
2039-12-03

AI Technical Summary

Technical Problem

Existing obesity treatments have limited effects on weight loss and are often accompanied by serious side effects. In particular, GLP-1 receptor agonists are prone to gastrointestinal side effects at large doses, which are poor tolerant and lack tolerance. A therapeutic agent that is effective in controlling blood sugar and reducing weight.

Method used

A long-acting modified glucagon peptide analog has been developed, with dual agonism of glucagon/glucagon-like peptide-1 receptors, enhanced by specific amino acid replacement and polyethylene glycol modification. The chemical stability and biological half-life of the drug are enhanced, and the agonistic activity of the GLP-1/GC receptor is enhanced.

Benefits of technology

This drug significantly reduces weight and reduces blood sugar, has better application potential. Compared with existing drugs, it has longer half-life in the body, has fewer side effects, and can effectively control blood sugar and weight.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0002300223820000121
    Figure BDA0002300223820000121
  • Figure BDA0002300223820000131
    Figure BDA0002300223820000131
  • Figure BDA0002300223820000132
    Figure BDA0002300223820000132
Patent Text Reader

Abstract

The present invention provides a long-acting modified glucagon peptide analog or its salt and its use. The long-acting modified glucagon peptide analog has the general formula I: X-Y-Z, wherein X is a polypeptide having a sequence of the general formula I, Y is a connecting arm connecting the polypeptide and a macromolecular polymer unit; Z is a macromolecular polymer unit, and X represents the general formula I: HX 2 QGTFTSDX 10 SKYLX 15 EX 17 AAX 20 E FX 23 X 24 WlX 28 X 29 , where X 2 , X 10 , X 12 , X 15 , X 17 , X 18 , X 20 , X 23 , X 24 , X 28 , X 29 The definition of is consistent with that in the claims and the specification. The long-acting modified glucagon peptide analog of the present invention has a dual agonist effect on GC / GLP-1 receptors, can effectively lower blood sugar while reducing weight and improving body fat levels, has a significant and long-lasting effect, better retains in vivo activity compared to the prior art, and has application potential in the treatment of metabolic diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of pharmaceutical biotechnology, and specifically relates to a long-acting modified glucagon peptide analog or a salt thereof, and its application in preparing drugs for treating obesity and diseases related thereto, such as diabetes, metabolic syndrome, non-alcoholic fatty liver, cardiovascular and nervous system diseases. Background Art

[0002] Obesity is a risk factor for many diseases and has become a global public health issue. In particular, the incidence and progression of common diseases including metabolic syndrome, cardiovascular disease, and non-alcoholic fatty liver disease are closely related to obesity. Several large-sample clinical studies have found that compared with people of normal weight, the incidence of multiple cardiovascular and metabolic diseases is higher in people with a BMI of 25.0–29.9 kg / m 2 30.0–34.9 kg / m 2 and BMI > 35.0 kg / m 2 The weight loss rate of T2DM patients is 2, 5, and 15 times higher than that of those who are overweight, obese, or severely obese (Lancet 2, e277–e285, 2017). Studies have shown that 80-90% of T2DM patients are overweight or obese. Moderate weight loss (4-5 kg) is beneficial for preventing and controlling the disease, including reducing the incidence of disease, controlling blood sugar, and disability (mortality) rate (Curr. Med. Res. Opin. 2011, 27(7), 1431-1438.).

[0003] Diet control and exercise are the most ideal means of weight loss, but they are generally ineffective. Drug interventions for obesity have limited efficacy or multiple risks, including serious cardiovascular effects and side effects such as psychiatric symptoms caused by central nervous system effects. So far, few drugs can achieve a weight loss of more than 5-10% when used alone. Among T2DM treatment drugs, only SGLT2 inhibitors and GLP-1 receptor agonists have a positive effect on weight control. Bariatric surgery is effective, but the surgical risks are high, and the long-term effects remain uncertain.

[0004] The blood sugar and energy regulation signal system of the body is maintained in a delicate balance by multiple factors, including different polypeptide hormones. Proglucagon is a precursor polypeptide with 158 amino acids, which is processed in different tissues to produce glucagon (GC), glucagon-like peptide-1, 2 (GLP-1, 2) and gastrin and other derivative peptides of proglucagon. These hormones are involved in the regulation of various physiological functions such as glucose homeostasis, insulin secretion, gastric emptying, intestinal growth and food intake. GC is a derivative peptide containing 29 amino acids corresponding to amino acids 33 to 61 of proglucagon. It is processed and produced in pancreatic α cells and acts on the liver under stress conditions such as hunger and cold. It raises blood sugar levels to normal range through sugar decomposition and gluconeogenesis. In addition to the effect of raising blood sugar, the results of animal and human experiments show that GC also has the effects of fever, increased satiety, lipolysis, fat oxidation, ketosis, etc. Long-term administration can improve energy metabolism, including weight loss.

[0005] GLP-1 is a derivative peptide containing 37 amino acid residues corresponding to amino acids 72 to 108 of proglucagon. It is secreted by intestinal L cells in response to meals, acts on pancreatic β-cells to promote insulin secretion, and antagonizes GC receptors to inhibit blood sugar rise. GLP-1 receptor agonists have been marketed as hyperglycemia treatment agents for diabetic patients, including short-acting exenatide, liraglutide, lixisenatide (1 to 2 times / day), and long-acting albiglutide, dulaglutide, Byuderon, and semaglutide (1 time / week). GLP-1 receptor agonist drugs have a safe and unique blood sugar-lowering effect, but when taking into account the weight loss effect, large doses are generally required. At large doses, these drugs are prone to gastrointestinal side effects and poor tolerance. Therefore, there is still a need for more tolerable therapeutic agents that can effectively control blood sugar and reduce weight.

[0006] Oxintomodulin (OXM) is a hormone produced in the intestine during the post-translational modification of proglucagon. It is secreted from ileal L-cells in response to meals together with hormones such as GLP-1. The acute effects of OXM include inhibition of gastric emptying, gastric and pancreatic exocrine secretion, food intake, resting energy expenditure, etc., which can produce a weight loss effect. The specific receptor of OXM has not yet been identified, but studies have found that OXM is an endogenous GCGR / GLP-1R dual agonist, and its activity on the two receptors is weaker than the natural ligands of each receptor. In animal and human experiments, it was found that peripheral administration of OXM can reduce food intake and weight loss, increase metabolic rate and energy expenditure, especially related to activity, in obese subjects. In particular, in clinical trials, large doses of peripheral administration of OXM can reduce weight while reducing the probability of common gastrointestinal side effects such as nausea and vomiting. Therefore, treatment based on OXM or GLP-1 / GCGR dual agonists shows potential application value for obesity and obese diabetes, but so far, no related drugs have been marketed. Summary of the invention

[0007] One object of the present invention is to provide a long-acting modified glucagon peptide analog or a salt thereof, which has a dual agonist effect on glucagon / glucagon-like peptide-1 receptors and has greater potential in the preparation of drugs for treating diseases such as diabetes, obesity, metabolic syndrome and non-alcoholic fatty liver disease due to its long-acting properties.

[0008] Another object of the present invention is to provide a pharmaceutical composition comprising a long-acting modified glucagon peptide analog or a salt thereof of the present invention.

[0009] Another object of the present invention is to provide a use of a long-acting modified glucagon peptide analog or a salt thereof of the present invention. Specifically provided is the use of the glucagon peptide analog and a salt thereof in the preparation of therapeutic drugs for treating metabolic diseases such as diabetes, obesity, non-alcoholic fatty liver disease, and liver fibrosis, neurodegenerative diseases, etc.

[0010] The objectives of the present invention are achieved through the following technical solutions.

[0011] In one aspect, the present invention provides a long-acting modified glucagon peptide analog or a salt thereof, wherein the peptide analog has a structure of general formula I.

[0012] General formula Ⅰ:

[0013] X—Y—Z

[0014] Wherein, X is a polypeptide having a sequence of general formula I, Z is a macromolecular polymer unit, and Y is a connecting arm connecting the polypeptide and the macromolecular polymer unit;

[0015] X represents the general formula ⅰ:

[0016] HX 2 QGTFTSDX 10 SKYLX15EX 17 AAX 20 EFX 23 X 24 WlX 28 X 29

[0017] in,

[0018] X 2 is Ser, D-Ser, D-Ala or Aib;

[0019] X 10 is Tyr, Lys or Leu;

[0020] X 15 Asp or Glu;

[0021] X 17 is Arg or Gln;

[0022] X 20 Lys or Gln;

[0023] X 23 for Val or Ile;

[0024] X 24 is Lys or Ala;

[0025] X 28 is Ala or Ser;

[0026] X 29 Thr, Sar or not present;

[0027] N-terminus free or amidated;

[0028] Site X 10 ,X 24 In the sequence, there is only one Lys site at the same time;

[0029] Y is a short peptide chain consisting of γ-Glu, Gly, Ser, and Cys with a sequence of 3-6 amino acids, connected to X 10 or X 24 Lys side chain of the site;

[0030] The macromolecular polymer unit represented by Z is a branched polyethylene glycol;

[0031] The polypeptide sequence of general formula I of the present invention is characterized in that:

[0032] X2 Ser or Aib;

[0033] X 10 is Tyr or Lys;

[0034] X 15 Glu;

[0035] X 23 for Ile;

[0036] X 24 is Lys or Ala;

[0037] X 28 is Ala or Ser;

[0038] X 29 Thr, Sar or not present;

[0039] Site X 10 ,X 24 In the , only one site is Lys at the same time;

[0040] N-terminal amidation;

[0041] In the polypeptide sequence of the general formula I of the present invention, when X 17 When X is Arg, 20 is Lys or Gln; when X 17 When X is Gln, 20 For Lys;

[0042] In the structure of the general formula I of the present invention, the connecting arm represented by Y has a peptide chain structure selected from the following sequences:

[0043] γEγEGSSCG,γEGSSCG,γEγEGSCG,γEGSCG,GSγESCγEG,GSγECG,GSSCGγEγE,GSSGCγE,GSCGγE,GS CγEG,γEγECG,γE CG;

[0044] In the general formula I structure of the present invention, Z represents a branched polyethylene glycol, and the molecular weight of the polyethylene glycol is in the range of 20-60KD; preferably 40-60KD, more preferably 40±10%KD;

[0045] The polyethylene glycol unit of the present invention is covalently coupled to the Cys residue side chain on the connecting arm via a maleimide activation group;

[0046] Structure of glucagon-derived peptide: Endogenous GLP-1 is a derivative peptide containing 37 amino acid residues (7-36 / 37) corresponding to amino acids 72 to 108 of proglucagon, and its amino acid sequence is HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR (7-36) (SEQ.ID.NO.1), HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG (7-37), and its C-terminus is free or amidated. Endogenous GC is a derivative peptide containing 29 amino acids corresponding to amino acids 33 to 61 of proglucagon, and its amino acid sequence is: HSQGTFTSDYSKYLDSRRAQDFVQWLMNT (SEQ.ID.NO.2), and its C-terminal carboxyl group is free. The amino acid sequences of natural GLP-1 and GC have 47% homology (Andreas Evers et al., J. Med. Chem. 2017, 60, 4293-4303), and the N-terminal sequences of the two are highly conserved. GLP-1 is highly selective for its receptor, while GC is also a weak agonist of the GLP-1 receptor. The GC sequence is an ideal lead structure for designing GLP-1 / GCGR dual agonists, and many documents have disclosed related technical solutions. The amino acid sequence of OXM is HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA (SEQ.ID.NO.3), which contains the original sequence of GC (1-29) and the insertion peptide-1 (IP-1, 30-37) corresponding to the amino acid sequence 82-89 of pre-proglucagon.

[0047] In the embodiments of the present invention, the GC sequence is subjected to amino acid site substitutions that help improve the GLP-1R agonist activity using known methods: including in some embodiments, Ser2 is replaced with Aib, and corresponding substitutions are made to sites 16-20, sites 21-23, and specific sites of the C-terminal fragment of the site are replaced with appropriate charged amino acids in order to obtain a sequence with an appropriate activity-to-potency ratio. For example, in some specific embodiments, 16 Ser is replaced by Glu, while 18Arg is replaced by Ala, and 20Gln is replaced by Lys; in other embodiments, position 23Val is replaced by Ile.

[0048] Generally, making as few changes as possible to the natural sequence is beneficial to maintaining homology, but the endogenous proglucagon sequence has many drugability problems: the N-terminal dipeptide is easily recognized by dipeptidyl kininase in the body and is hydrolyzed and inactivated, resulting in a short plasma half-life (≤12min); the physical properties are unstable, i.e., the isoelectric point (pI) is 7.6, which is neutral, and it is hydrophobic and has poor solubility, and it is easy to aggregate and precipitate in solution; the sequence contains amino acids such as Met, Asp, Asn that are easily oxidized or racemized, resulting in unstable chemical properties.

[0049] In order to improve the chemical stability of the peptide sequence, amino acids such as Asp, Met, Gln, Asn in the sequence were replaced, such as 15, 21Asp replaced by Glu; 27Met replaced by Leu; 28Asn replaced by Glu or Ala.

[0050] In a preferred embodiment of the present invention, in order to improve the metabolic stability of the polypeptide, 2Ser is usually replaced by Aib or D-Ser.

[0051] Polyethylene glycol (PEG) modification is a well-known polypeptide / protein long-acting technology in the art. Generally, the target product is obtained by coupling the activated end group of PEG to the Lys side chain amino group or Cys side chain thiol group in the polypeptide or protein sequence. The modification scheme can be a random site or a specific site. In the public patent literature related to GC / GLP-1 dual receptor agonists, PEG modification is used as a long-acting agent: CN200880012086.2, CN200980132562.9, and CN201310158648.7 mutate the 24 site to Cys, and CN200780006185.5 mutates the C-terminal site of the OXM sequence to Cys and couples PEG. The common feature of these schemes is that the linear or branched PEG with a molecular weight of 20 to 40KD is coupled with the side chain thiol of Cys at a specific site on the peptide chain through the Michael addition reaction with the maleimide activated end group to obtain the target modifier, and the binding is stable and irreversible. This method has the advantages of high reaction specificity, single target product, mild reaction conditions, little or no other impurities, and easy quality control. However, the thiol side chain of Cys is relatively short, and the rigid structure formed by covalent linkage with the maleimide group and the huge PEG molecule on it lead to changes in the flexible structure of the polypeptide, shielding the active site and affecting its binding with the receptor. The active polypeptide sequence is generally short, and PEG modification at any site affects the activity of the target modifier, especially when the modification site is close to the active site in the sequence.

[0052] The inventors found in their research that the change of the C-terminal sequence of the designed GC / GLP-1 dual agonist polypeptide has a great influence on the activity of the GC receptor. According to the public method, the appropriate site of the C-terminal is mutated to Cys and then modified with PEG, and its in vitro and in vivo activity is significantly reduced, resulting in an increase in the dosage in the in vivo test. This is very unfavorable for clinical application.

[0053] The side chain of Lys is longer than that of Cys and is relatively more flexible. However, the sequence of Lys contains multiple key active sites, plus the α-amino group. When Lys is used as the modification site, the site selectivity is poor, the reaction products are complex, and it is difficult to achieve batch-to-batch quality uniformity. Quality control is difficult, and even worse, there are problems such as greatly reduced or disappeared activity.

[0054] The technical solution provided by the present invention is different from the existing disclosed technical solution. After replacing the specific site in the sequence with Lys, the side chain is further extended with a short peptide chain containing hydrophilic and negatively charged amino acid residues to increase the flexibility of the side chain. At the same time, the short peptide chain contains Cys residues to facilitate PEG modification. In some preferred embodiments, the short peptide chain is connected to the 10Lys side chain of the main chain sequence, and in other embodiments, it is on the 24Lys.

[0055] Peptide hormones are metabolized in the body mainly through enzymatic degradation and renal clearance pathways, among which renal clearance is dominant and is the main factor affecting the half-life of peptide drugs in the body. Structural modifications on the side chains of some amino acid residues in the peptide sequence, especially alkylation or conjugation of macromolecular groups such as polyethylene glycol, can delay renal clearance and effectively prolong the biological half-life.

[0056] In the embodiment provided by the present invention, the molecular weight of the polyethylene glycol is between 20,000 and 50,000 Daltons;

[0057] The polyethylene glycol of the present invention can be obtained through various routes, including commercial routes or self-preparation according to methods known in the art.

[0058] The PEG modification of the present invention can be achieved by any method known in the art, including via acylation, reductive alkylation, Michael addition, thiol alkylation or other chemical selective conjugation methods through active groups (e.g., aldehyde, amino, ester, thiol, α-haloacetyl, maleimido or hydrazine) of the PEG moiety. In a specific embodiment of the present invention, the PEGylated polypeptide is connected through a thioether bond by Michael addition reaction, i.e., modifying the sulfhydryl side chain of Cys with maleimide-activated PEG.

[0059] The polyethylene glycol in the preferred embodiment of the present invention includes modified PEG, which refers to monomethoxy PEG, and is preferably a branched PEG, whose terminal group is activated with a maleimide group;

[0060] In a preferred embodiment of the present invention, the polyethylene glycol modification of the polypeptide is achieved by connecting maleimido-activated polyethylene glycol to the sulfhydryl group on the side chain of the cysteine ​​residue. Maleimido polyethylene glycol can be obtained through commercial channels or prepared by itself according to techniques known in the art.

[0061] Through the above technical scheme, as shown in the experimental results of Example 4, the target modifier using the implementation scheme of the present invention showed a significantly stronger weight loss effect than the existing disclosed technical scheme in the in vivo test of DIO model mice, and the hypoglycemic effect was equivalent to the positive control and other comparative test compounds, and had better application potential.

[0062] The present invention provides a peptide with dual agonist effect of GLP-1 / glucagon, which has the following activity characteristics through the aforementioned structural design of the present invention: the polypeptide provided by the present invention has at least 1% receptor agonist activity compared with the natural ligand of each GLP-1 / GCGR receptor. Through a series of structural optimization designs, the intensity of the agonist effect on the GLP-1 receptor is equivalent to the endogenous natural ligand GLP-1 (7-36 / 37) or equivalent to 150%, 200%, 300%, 500%, 1000% or more of the natural ligand. The agonist activity on the glucagon receptor is equivalent to the endogenous ligand (GC) or equivalent to 1000-10% of the intensity of the endogenous agonist. In certain embodiments, the polypeptide provided by the present invention has a receptor agonist activity equal to or stronger than that of the endogenous ligand. In other embodiments, the agonist effect on the GLP-1 receptor is stronger than that on the glucagon receptor, or the agonist effect on the two receptors is equal. The relative activity strength against GLP-1 and glucagon receptors can be expressed by a potency ratio, that is, the potency ratio of the polypeptide comprising the general formula I sequence provided by the present invention against GLP-1 / glucagon receptor includes but is not limited to 10:1, 9:1, 8:1, 7:1, 6:1, 3:1, 1:1 to 1:10.

[0063] In another aspect, the present invention provides a pharmaceutical composition comprising at least one polypeptide represented by general formula I or a salt thereof.

[0064] Preferably, the composition further comprises pharmaceutically acceptable carriers, diluents and other auxiliary materials.

[0065] Preferably, the composition of the present invention is composed of the polypeptide analog of the general formula I and one or more pharmaceutically acceptable excipients, including water-soluble fillers, pH regulators, stabilizers, water for injection, osmotic pressure regulators, and the like.

[0066] Preferably, the water-soluble filler includes but is not limited to mannitol, low molecular weight dextran, sorbitol, polyethylene glycol, glucose, lactose, galactose, etc.; the pH adjuster includes but is not limited to organic or inorganic acids such as citric acid, phosphoric acid, lactic acid, tartaric acid, hydrochloric acid, and physiologically acceptable inorganic bases or salts such as potassium hydroxide, sodium hydroxide, ammonium hydroxide, sodium carbonate, potassium carbonate, ammonium carbonate, potassium bicarbonate, sodium bicarbonate, and ammonium bicarbonate salts; the stabilizer includes but is not limited to EDTA-2Na, sodium thiosulfate, sodium pyrosulfite, sodium sulfite, dipotassium hydrogen phosphate, sodium bicarbonate, sodium carbonate, arginine, lysine, glutamic acid, aspartic acid, polyethylene glycol, polyvinyl alcohol, polyvinyl pyrrolidone, carboxyl / hydroxycellulose or its derivatives such as HPC, HPC-SL, HPC-L or HPMC, cyclodextrin, sodium dodecyl sulfate or tris(hydroxymethyl)aminomethane, etc.; the osmotic pressure regulator includes but is not limited to sodium chloride or potassium chloride.

[0067] In another aspect of the present invention, the use of the derivative peptide of the present invention shown in general formula I, its salt or its composition in the preparation of a drug for treating diabetes, obesity, non-alcoholic fatty liver disease and the like is provided. Preferably, the composition of the present invention can be administered in the form of intravenous, intramuscular or subcutaneous injection or orally, rectally or nasally. The dosage range can be 5 μg-100 mg / time, depending on the treatment object, administration method, indication and other factors.

[0068] Another object of the present invention is to provide therapeutic uses of the glucagon-derived polypeptide and its salt described in the present invention. The embodiments of the present invention provide the use of the polypeptide analogs or their salts described in the present invention in the treatment of diseases selected from T2DM, obesity, fatty liver, non-alcoholic fatty liver, hyperlipidemia, metabolic syndrome, etc. Compared with simple GLP-1 receptor agonists, the polypeptide analogs of the present invention have the effects of promoting weight loss and preventing weight gain while more effectively lowering blood sugar, reversing insulin resistance, and have unexpected beneficial effects compared with existing drugs.

[0069] Synthesis and preparation of peptides:

[0070] The basic peptide chain of the GC-derived peptide having the general formula I structure provided in the present invention can be prepared by methods well known in the art:

[0071] 1) Synthesis by conventional solid-phase or liquid-phase methods, stepwise or by fragment assembly;

[0072] 2) expressing the nucleic acid construct encoding the polypeptide in a host cell and recovering the expression product from the host cell culture;

[0073] 3) affecting the cell-free in vitro expression of a nucleic acid construct encoding a polypeptide and recovering the expression product;

[0074] Alternatively, peptide fragments are obtained by any combination of methods 1), 2) or 3), and then these fragments are connected to obtain the target peptide.

[0075] In the embodiment provided by the present invention, preferably, the target peptide is prepared using the Fmoc solid phase synthesis method, which is well known to those skilled in the art.

[0076] The ε-amino group of Lys with modifiable side chains can be protected by Mtt or Dde. After the main chain synthesis is completed, an appropriate reagent, generally hydrazine hydrate of an appropriate concentration, is used to remove the protecting group, and the side chain is further extended by the Fmoc solid phase synthesis method.

[0077] After the side chain synthesis is completed, the peptide chain is cut from the resin, washed, and dried according to the general method to obtain a crude polypeptide.

[0078] The crude polypeptide can be separated from the target product by suitable methods known in the art. Applicable methods include but are not limited to ultrafiltration, dialysis or chromatography. In the embodiment of the present invention, it is preferred to purify the target polypeptide by preparative high performance liquid chromatography (≥90%).

[0079] PEG modification method: In the specific embodiment provided by the present invention, the PEGylation modification of the target polypeptide is completed by the following method: the activated PEG is reacted with the target polypeptide of SEQ ID NO1-35 of the present invention at pH 5.0-8.0, the molar ratio of PEG to peptide is 1:10-10:1, the reaction time is 0.5-12 hours, and the reaction temperature is 4-37°C.

[0080] The target modified substance is purified by methods commonly used in the art, including filtration, dialysis, high performance liquid chromatography, ion exchange chromatography or molecular sieve chromatography, including a single method or a stepwise combination of multiple methods described above.

[0081] Receptor activity assay: In embodiments of the present invention, the effect of the polypeptide on the GLP-1 / GC receptor is evaluated by affecting GLP-1 / GC receptor-mediated cAMP production in vitro.

[0082] Regulatory effect on body weight and blood sugar: In the embodiment of the present invention, a high-fat diet obese diabetic mouse (Dio) model was used to evaluate the effect of the polypeptide provided by the present invention on body weight and blood sugar. The results showed that the polypeptide analogs provided by the present invention have significant weight loss and blood sugar lowering effects, and the weight loss effect is significantly better than the positive control drug, suggesting that it has potential advantages in the preparation of drugs for the control of metabolic diseases such as obesity and the treatment of diabetes. DETAILED DESCRIPTION

[0083] The present invention will be further described below in conjunction with specific examples. These examples are only for explaining the present invention and are not intended to limit the present invention in any way.

[0084] Explanation of amino acid abbreviations:

[0085] Gly:Glycine (G)

[0086] Ala: Alanine (A)

[0087] Val:Valine (V)

[0088] Leu:Leucine (L)

[0089] Phe: Phenylalanine (F)

[0090] Trp:Tryptophan (W)

[0091] Ser: Serine (S)

[0092] Thr:Threonine (T)

[0093] Glu: Glutamic acid (E)

[0094] Gln: Glutamine (Q)

[0095] Asp:Aspartic acid (D)

[0096] Asn:Asparagine (N)

[0097] Tyr: Phenylalanine (Y)

[0098] Arg:Arginine(R)

[0099] Lys:Lysine (K)

[0100] His: Histidine (H)

[0101] Aib: α-aminoisobutyric acid

[0102] Ado:8-amino-3,6-dioxaoctanoic acid

[0103] Description of reagent abbreviations

[0104] Boc: tert-Butyloxycarbonyl

[0105] Tert-Bu: tert-butyl

[0106] DCM: dichloromethane

[0107] DIC: Diisopropylcarbodiimide

[0108] Fmoc:9-Fluorenylmethoxycarbonyl

[0109] HoBt:1-Hydroxybenzotriazole

[0110] HBTU:2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetramethyl-uronium hexafluorophosphate

[0111] HATU:O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyl-uronium hexafluorophosphate

[0112] Mtt:4-Methyltrityl

[0113] NMP: N-Methylpyrrolidone

[0114] DMF: Dimethylformamide

[0115] Pbf:2,2,4,6,7-pentamethyldihydrobenzofuran

[0116] Dde: 1-(4,4-dimethyl-2,6-dioxocyclohexylene)-3-methyl-butyl

[0117] Trt: Triphenylmethyl

[0118] EDT: Ethylene dithiol

[0119] TFA: Trifluoroacetic acid

[0120] TIS: Triisopropylsilane

[0121] FBS: Fetal bovine serum

[0122] Example 1.

[0123] Synthesis of target sequence peptides

[0124] 1) Synthesis: Using the Fmoc strategy, the peptide was synthesized using a CS 336 peptide synthesizer (CS Bio) in the following steps:

[0125] a) In the presence of an activator system, a resin solid phase carrier and an Fmoc-protected C-terminal amino acid are coupled to obtain Fmoc-amino acid-resin; wherein, amino resins such as Rink Amide AM, Rink Amide, Rink MBHA, etc. are used to synthesize C-terminal amidated polypeptides.

[0126] b) Peptide chain extension: amino acids were connected in the order of amino acids in the peptide sequence by solid phase synthesis to obtain peptide-resin conjugates with N-terminal and side chain protection; amino acids with side chains were protected as follows: tryptophan was protected with Boc (tert-butyloxycarbonyl), glutamic acid was protected with OtBu (tert-butyloxycarbonyl), lysine was protected with Boc (tert-butyloxycarbonyl), glutamine was protected with Trt (trityl), tyrosine was protected with tBu (tert-butyl), serine was protected with Trt (trityl) or tBu (tert-butyl), aspartic acid was protected with OtBu (tert-butyloxycarbonyl), threonine was protected with tBu (tert-butyl), and histidine was protected with Trt (trityl) or Boc (tert-butyloxycarbonyl). The coupling activators used were HOBT / HBTU / DIEA and HOBT / HATU / DIEA, and the reaction efficiency was detected by the ninhydrin method.

[0127] c) Deprotection of the ε-amino group of lysine:

[0128] The fully protected peptide-resin synthesized in the above step was washed three times with NMP-DCM (1:1 V / V), and a freshly prepared 2.0% hydrazine hydrate solution in NMP was added, stirred at room temperature for 12.0 minutes, filtered, and repeated twice, and the resin was washed three times with DCM and NMP respectively.

[0129] d) Extension of the side chain: After the ε-amino group of lysine is deprotected, the side chain short peptide is synthesized according to the method of step b) to extend the side chain.

[0130] e) Cleavage and complete deprotection of the polypeptide on the resin: TFA / EDT / TIS / H2O (92.5:2.5:2.5:2.5 v / v) solution, react at room temperature for 90 minutes, deprotect and remove the resin. Filter the filtrate, precipitate the crude polypeptide with excess ether, centrifuge, collect the precipitate, remove the protecting group and the resin at the same time, wash the precipitate with a small amount of ether, and dry it under vacuum to obtain the crude polypeptide.

[0131] 2) Purification: The crude glucagon-like peptide-1 analog is dissolved in water or 10-15% acetonitrile (10-50 mg / ml), and 50-100 mM dithiothreitol DTT or β-mercaptoethanol is added for denaturation. The peptide is separated and purified by preparative HPLC, C18 column, acetonitrile-water-trifluoroacetic acid system, concentrated, and freeze-dried to obtain a pure polypeptide with free thiol groups.

[0132] The sequences of the synthesized polypeptides are shown in Table 1 below.

[0133] Table 1. Synthesized peptide sequences

[0134]

[0135]

[0136] Note: K* is a Lys with an extended sequence Y attached to the side chain.

[0137] Example 2

[0138] Preparation of Mal-(mPEG)2 (40KDa) modified form of SEQ.ID.NO.4 (compound PegDA001)

[0139] 1) Connection:

[0140] The polypeptide shown in SEQ ID NO:3 was dissolved in a 50 mM sodium phosphate buffer solution at pH 6 containing 5 mM EDTA at a concentration of 2 mg / mL. A 1.5-fold molar amount of solid PEG-maleimide was added, stirred to dissolve, and reacted at room temperature for 0.5-8 hours. The reaction was monitored by HPLC, terminated with 5 mM β-mercaptoethanol, and purified after leaving at room temperature for 30 minutes.

[0141] 2) Purification: Preparative ion exchange column chromatography was used, with SP Sepharose HP filler, and linear gradient elution was performed with 0-500 mM sodium chloride pH 6 phosphate buffer solution. The effluent was detected by HPLC and SDS-electrophoresis, and the PEG-polypeptide fraction was collected, desalted by Sephadex G50 chromatography column, and freeze-dried.

[0142] 3) The pure polypeptide was subjected to full molecular weight scanning by MALDI-TOF, and the average molecular weight was determined to be m / z 42280.5203Da.

[0143] The PegDA series compounds PegDA001-017 shown in Table 2 were prepared using the above method.

[0144] Table 2 Polypeptide polyethylene glycol modification

[0145]

[0146]

[0147] Example 3

[0148] Chinese guinea pig lung cells transfected with human GLP-1 receptor and HEK293 cells transfected with GC receptor were inoculated into 96-well culture plates (200,000 cells / well), washed with Hanks' balanced salt buffer, and incubated with different concentrations of the tested peptide samples (10-5 to 10-12 mol / L) in the presence of 200 mmol / L 3-isobutyl-1-methyl rubiacein at 37°C for 20 min. The medium was removed, the cells were dissolved, and the cAMP value was determined. The determination method was referred to the instructions of the analysis kit. The 50% effective concentration (EC50) was calculated using Origin software. For comparison, the main chain (X) variant of SEQ.ID.NO.28 with a mutation at position 24 to Cys (24CysID28X) and its PEG modification (peg24CysID28X) were simultaneously determined. The results are shown in Table 3.

[0149] Table 3. GLP-1 / GC receptor agonism

[0150]

[0151]

[0152] Example 4

[0153] Example 2 Effects of compounds PegDA006, PegDA012 and comparative compound 24CysID28X on body weight and blood glucose in Dio mice

[0154] 1) Impact on body weight

[0155] C57BL / 6J mice, 35, model group (n = 30) was fed with H10060 high-fat diet to induce obesity (DIO), blank control group (n = 5) was fed with standard diet, and both were fed for 34 weeks. One day before the first administration, the model group was randomly divided into groups according to body weight (average body weight range 45.0-52.0g), 5 mice in each group, namely model control group, positive control group (semaglutide), test sample group (1#-3# were compounds PegDA006, PegDA012, 24CysID28X, respectively). The blank control group and model control group were subcutaneously administered with normal saline every day, and the positive control group and test sample group were subcutaneously injected every day for a total of 9 days. The weight of the animals was weighed and recorded every day, and the weight change rate (%) was calculated by comparing the last administration day with the starting weight. The results are shown in Table 4.

[0156] Calculation formula: (starting weight - last weight) / starting weight = weight change rate (%)

[0157] A positive value indicates a decrease, and a negative value indicates an increase.

[0158] Table 4 Weight loss rate of animals in each group at the last unfasted stage compared with day 1 (%, n = 5)

[0159] Dosing days Blank control group Model control group Positive control group 1# 2# 3# 9 -1.43 10.05 8.53 18.50 23.26 10.18

[0160] 2) Hypoglycemic effect on glucose load model animals:

[0161] DIO mice were fasted for 16 hours, and then given glucose solution (1 g / kg) intraperitoneally for glucose tolerance test 1 hour after subcutaneous injection. Blood glucose levels were measured at 0.5, 1, and 1.5 hours after glucose administration, and the area under the blood glucose concentration curve (AUC) was calculated and compared with the model control group, and the blood glucose inhibition rate (%) was calculated. The results are shown in Table 5.

[0162] Table 5 Effects of compounds on blood glucose levels in DIO mice after glucose loading

[0163]

[0164] ** : Compared with the model control group, P < 0.01; * :Compared with the model control group P<0.05

[0165] ## : P<0.01 compared with the positive control group; # :Compared with the positive control group P<0.05

[0166] △△ :Compared with the blank control group, P<0.01

[0167] Conclusion: As shown in Table 4 and Table 5, compared with the model group, the positive drug and the test compound of the present invention showed significant weight loss effect and significantly improved glucose tolerance. Among them, the compounds PegDA006 (1#) and PegDA012 (2#) provided by the present invention, whose side chains are extended with flexible peptide fragments and then PEG-modified, showed a more significant weight loss effect compared with the control compound 24CysID28X (3#) (Table 4), indicating that the technical measures of the present invention are more helpful to retain the agonist activity of the PEG-modified compound on GC receptors in vivo. Sequence Listing <110> Tianjin Pharmaceutical Research Institute Co., Ltd. <120> A long-acting modified glucagon peptide analog, or its salt, and its use <160> 39 <170> SIPOSequenceListing 1.0 <210> 1 <211> 30 <212> PRT <213> GLP-1 <400> 1 His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 1 5 10 15 Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg 20 25 30 <210> 2 <211> 29 <212> PRT <213> Glucagon <400> 2 His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 1 5 10 15 Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 3 <211> 37 <212> PRT <213> Oxintomodulin <400> 3 His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 1 5 10 15 Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr Lys Arg Asn 20 25 30 Arg Asn Asn Ile Ala 35 <210> 4 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2) <223> Xaa is Aib <220> <221> BINDING <222> (10)..(10) <223> Lysine side chain with extended sequence γEGSSCG <220> <221> UNSURE <222> (2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 4 His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Glu Glu 1 5 10 15 Arg Ala Ala Gln Glu Phe Ile Ala Trp Leu Leu Glu Thr 20 25 <210> 5 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2) <223> Xaa is Aib <220> <221> BINDING <222> (24)..(24) <223> Lysine side chain with extended sequence γEGSSCG <220> <221> UNSURE <222> (2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 5 His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Glu Glu 1 5 10 15 Arg Ala Ala Lys Glu Phe Ile Lys Trp Leu Leu Ala Thr 20 25 <210> 6 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2)..(2) <223> Xaa is Aib <220> <221> BINDING <222> (10)..(10) <223> Lysine side chain with extended sequence γEGSSCG <220> <221> UNSURE <222> (2)..(2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 6 His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Glu Glu 1 5 10 15 Arg Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Ala Thr 20 25 <210> 7 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2)..(2) <223> Xaa is Aib <220> <221> BINDING <222> (24)..(24) <223> Lysine side chain with extended sequence γEGSSCG <220> <221> UNSURE <222> (2)..(2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 7 His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Glu Glu 1 5 10 15 Arg Ala Ala Lys Glu Phe Ile Lys Trp Leu Leu Glu Thr 20 25 <210> 8 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2)..(2) <223> Xaa is Aib <220> <221> BINDING <222> (10)..(10) <223> Lysine side chain with extended sequence γEGSSCG <220> <221> UNSURE <222> (2)..(2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 8 His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Glu Glu 1 5 10 15 Arg Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Glu Thr 20 25 <210> 9 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2) <223> Xaa is Aib <220> <221> BINDING <222> (24)..(24) <223> Lysine side chain with extended sequence γEGSSCG <220> <221> UNSURE <222> (2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 9 His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Glu Glu 1 5 10 15 Arg Ala Ala Gln Glu Phe Ile Lys Trp Leu Leu Glu Thr 20 25 <210> 10 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2) <223> Xaa is Aib <220> <221> BINDING <222> (24)..(24) <223> Lysine side chain with extended sequence γEGSSCG <220> <221> UNSURE <222> (2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 10 His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Glu Glu 1 5 10 15 Arg Ala Ala Gln Glu Phe Ile Lys Trp Leu Leu Ala Thr 20 25 <210> 11 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2) <223> Xaa is Aib <220> <221> BINDING <222> (10)..(10) <223> Lysine side chain with extended sequence γEGSSCG <220> <221> UNSURE <222> (2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 11 His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Glu Glu 1 5 10 15 Arg Ala Ala Gln Glu Phe Ile Ala Trp Leu Leu Ala Thr 20 25 <210> 12 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2)..(2) <223> Xaa is Aib <220> <221> BINDING <222> (24)..(24) <223> Lysine side chain with extended sequence γEGSSCG <220> <221> UNSURE <222> (2)..(2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 12 His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Glu Glu 1 5 10 15 Arg Ala Ala Lys Glu Phe Ile Lys Trp Leu Leu Ser Thr 20 25 <210> 13 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2)..(2) <223> Xaa is Aib <220> <221> BINDING <222> (10)..(10) <223> Lysine side chain with extended sequence γEGSSCG <220> <221> UNSURE <222> (2)..(2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 13 His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Glu Glu 1 5 10 15 Arg Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Ser Thr 20 25 <210> 14 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2)..(2) <223> Xaa is Aib <220> <221> BINDING <222> (24)..(24) <223> Lysine side chain with extended sequence γEGSSCG <220> <221> UNSURE <222> (2)..(2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 14 His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Glu Glu 1 5 10 15 Arg Ala Ala Gln Glu Phe Ile Lys Trp Leu Leu Ser Thr 20 25 <210> 15 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2) <223> Xaa is Aib <220> <221> BINDING <222> (10)..(10) <223> Lysine side chain with extended sequence γEGSSCG <220> <221> UNSURE <222> (2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 15 His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Glu Glu 1 5 10 15 Arg Ala Ala Gln Glu Phe Ile Ala Trp Leu Leu Ser Thr 20 25 <210> 16 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2)..(2) <223> Xaa is Aib <220> <221> BINDING <222> (10)..(10) <223> Lysine side chain with extended sequence γEγEGSSCG <220> <221> UNSURE <222> (2)..(2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 16 His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Glu Glu 1 5 10 15 Arg Ala Ala Gln Glu Phe Ile Ala Trp Leu Leu Glu Thr 20 25 <210> 17 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2)..(2) <223> Xaa is Aib <220> <221> BINDING <222> (24)..(24) <223> Lysine side chain with extended sequence γEγEGSSCG <400> 17 His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Glu Glu 1 5 10 15 Arg Ala Ala Lys Glu Phe Ile Lys Trp Leu Leu Ala Thr 20 25 <210> 18 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2)..(2) <223> Xaa is Aib <220> <221> BINDING <222> (10)..(10) <223> Lysine side chain with extended sequence γEγEGSSCG <220> <221> UNSURE <222> (2)..(2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 18 His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Glu Glu 1 5 10 15 Arg Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Ala Thr 20 25 <210> 19 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2)..(2) <223> Xaa is Aib <220> <221> BINDING <222> (24)..(24) <223> Lysine side chain with extended sequence γEγEGSSCG <220> <221> UNSURE <222> (2)..(2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 19 His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Glu Glu 1 5 10 15 Arg Ala Ala Lys Glu Phe Ile Lys Trp Leu Leu Glu Thr 20 25 <210> 20 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2)..(2) <223> Xaa is Aib <220> <221> BINDING <222> (10)..(10) <223> Lysine side chain with extended sequence γEγEGSSCG <220> <221> UNSURE <222> (2)..(2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 20 His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Glu Glu 1 5 10 15 Arg Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Glu Thr 20 25 <210> twenty one <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2) <223> Xaa is Aib <220> <221> BINDING <222> (24)..(24) <223> Lysine side chain with extended sequence γEγEGSSCG <220> <221> UNSURE <222> (2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> twenty one His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Glu Glu 1 5 10 15 Arg Ala Ala Gln Glu Phe Ile Lys Trp Leu Leu Glu Thr 20 25 <210> twenty two <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2) <223> Xaa is Aib <220> <221> BINDING <222> (24)..(24) <223> Lysine side chain with extended sequence γEγEGSSCG <220> <221> UNSURE <222> (2)..(2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> twenty two His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Glu Glu 1 5 10 15 Arg Ala Ala Gln Glu Phe Ile Lys Trp Leu Leu Ala Thr 20 25 <210> twenty three <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2)..(2) <223> Xaa is Aib <220> <221> BINDING <222> (10)..(10) <223> Lysine side chain with extended sequence γEγEGSSCG <220> <221> UNSURE <222> (2)..(2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> twenty three His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Glu Glu 1 5 10 15 Arg Ala Ala Gln Glu Phe Ile Ala Trp Leu Leu Ala Thr 20 25 <210> twenty four <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2) <223> Xaa is Aib <220> <221> BINDING <222> (24)..(24) <223> Lysine side chain with extended sequence γEγEGSSCG <220> <221> UNSURE <222> (2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> twenty four His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Glu Glu 1 5 10 15 Arg Ala Ala Lys Glu Phe Ile Lys Trp Leu Leu Ser Thr 20 25 <210> 25 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2) <223> Xaa is Aib <220> <221> BINDING <222> (10)..(10) <223> Lysine side chain with extended sequence γEγEGSSCG <220> <221> UNSURE <222> (2)..(2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 25 His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Glu Glu 1 5 10 15 Arg Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Ser Thr 20 25 <210> 26 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2)..(2) <223> Xaa is Aib <220> <221> BINDING <222> (24)..(24) <223> Lysine side chain with extended sequence γEγEGSSCG <220> <221> UNSURE <222> (2)..(2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 26 His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Glu Glu 1 5 10 15 Arg Ala Ala Gln Glu Phe Ile Lys Trp Leu Leu Ser Thr 20 25 <210> 27 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2)..(2) <223> Xaa is Aib <220> <221> BINDING <222> (10)..(10) <223> Lysine side chain with extended sequence γEγEGSSCG <220> <221> UNSURE <222> (2)..(2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 27 His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Glu Glu 1 5 10 15 Arg Ala Ala Gln Glu Phe Ile Ala Trp Leu Leu Ser Thr 20 25 <210> 28 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2)..(2) <223> Xaa is Aib <220> <221> BINDING <222> (24)..(24) <223> Lysine side chain with extended sequence γEγEGSSCG <400> 28 His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu 1 5 10 15 Arg Ala Ala Lys Glu Phe Ile Lys Trp Leu Leu Ala Thr 20 25 <210> 29 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2) <223> Xaa is Aib <220> <221> BINDING <222> (24)..(24) <223> Lysine side chain with extended sequence γEγEGSSCG <220> <221> UNSURE <222> (2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 29 His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu 1 5 10 15 Arg Ala Ala Gln Glu Phe Ile Lys Trp Leu Leu Ala Thr 20 25 <210> 30 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2) <223> Xaa is Aib <220> <221> BINDING <222> (10)..(10) <223> Lysine side chain with extended sequence γEγEGSSCG <220> <221> UNSURE <222> (2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 30 His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Glu 1 5 10 15 Arg Ala Ala Gln Glu Phe Ile Ala Trp Leu Leu Glu Thr 20 25 <210> 31 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2) <223> Xaa is Aib <220> <221> BINDING <222> (24)..(24) <223> Lysine side chain with extended sequence γEγEGSSCG <220> <221> UNSURE <222> (2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 31 His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu 1 5 10 15 Arg Ala Ala Gln Glu Phe Ile Lys Trp Leu Leu Glu Thr 20 25 <210> 32 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2) <223> Xaa is Aib <220> <221> BINDING <222> (24)..(24) <223> Lysine side chain with extended sequence γEγEGSSCG <220> <221> UNSURE <222> (2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 32 His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu 1 5 10 15 Arg Ala Ala Lys Glu Phe Ile Lys Trp Leu Leu Ser Thr 20 25 <210> 33 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2)..(2) <223> Xaa is Aib <220> <221> BINDING <222> (10)..(10) <223> Lysine side chain with extended sequence γEGSSCG <220> <221> UNSURE <222> (2)..(2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 33 His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Glu 1 5 10 15 Arg Ala Ala Gln Glu Phe Ile Ala Trp Leu Leu Ser Thr 20 25 <210> 34 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2)..(2) <223> Xaa is Aib <220> <221> BINDING <222> (24)..(24) <223> Lysine side chain with extended sequence γEGSSCG <220> <221> UNSURE <222> (2)..(2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 34 His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu 1 5 10 15 Arg Ala Ala Lys Glu Phe Ile Lys Trp Leu Leu Ala Thr 20 25 <210> 35 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2) <223> Xaa is Aib <220> <221> BINDING <222> (24)..(24) <223> Lysine side chain with extended sequence γEGSSCG <220> <221> UNSURE <222> (2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 35 His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu 1 5 10 15 Arg Ala Ala Gln Glu Phe Ile Lys Trp Leu Leu Ala Thr 20 25 <210> 36 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2) <223> Xaa is Aib <220> <221> BINDING <222> (10)..(10) <223> Lysine side chain with extended sequence γEGSSCG <220> <221> UNSURE <222> (2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 36 His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Glu 1 5 10 15 Arg Ala Ala Gln Glu Phe Ile Ala Trp Leu Leu Glu Thr 20 25 <210> 37 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2) <223> Xaa is Aib <220> <221> BINDING <222> (24)..(24) <223> Lysine side chain with extended sequence γEGSSCG <220> <221> UNSURE <222> (2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 37 His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu 1 5 10 15 Arg Ala Ala Gln Glu Phe Ile Lys Trp Leu Leu Glu Thr 20 25 <210> 38 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2) <223> Xaa is Aib <220> <221> BINDING <222> (24)..(24) <223> Lysine side chain with extended sequence γEGSSCG <220> <221> UNSURE <222> (2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 38 His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu 1 5 10 15 Arg Ala Ala Lys Glu Phe Ile Lys Trp Leu Leu Ser Thr 20 25 <210> 39 <211> 29 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (2)..(2) <223> Xaa is Aib <220> <221> BINDING <222> (10)..(10) <223> Lysine side chain with extended sequence γEGSSCG <220> <221> UNSURE <222> (2)..(2) <223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu. <400> 39 His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Glu 1 5 10 15 Arg Ala Ala Gln Glu Phe Ile Ala Trp Leu Leu Ser Thr 20 25

Claims

1. A long-acting modified glucagon peptide analog or a salt thereof, characterized in that: The glucagon peptide analog has the following general formula I structure: General formula Ⅰ: X—Y—Z Wherein, X is a polypeptide having a sequence of general formula I, Z is a macromolecular polymer unit, and Y is a connecting arm connecting the polypeptide and the macromolecular polymer unit; X represents the general formula ⅰ: HX 2 QGTFTSDX 10 SKYLX 15 EX 17 AAX 20 EFX 23 X 24 WLLX 28 X 29 Wherein, the polypeptide amino acid sequence is shown in SEQ ID NO: 17, 28; Y is a short peptide chain consisting of γ-Glu, Gly, Ser, and Cys with a sequence of 3-6 amino acids, connected to X 24 The Lys side chain of the site, the amino acid sequence of the short peptide chain is γEγEGSSCG; The macromolecular polymer unit represented by Z is a branched polyethylene glycol, and the polyethylene glycol is Mal-(mPEG)2, with a molecular weight of 40KD.

2. The glucagon peptide analog or salt thereof according to claim 1, characterized in that The polyethylene glycol unit is covalently coupled to the Cys residue side chain on the connecting arm via a maleimide activated group.

3. A pharmaceutical composition comprising the glucagon peptide analog or a salt thereof according to any one of claims 1 to 2 and a pharmaceutically acceptable excipient.

4. Use of the glucagon peptide analog or a salt thereof according to any one of claims 1 to 2 in the preparation of a medicament for treating diabetes and obesity.